Boston Scientific Corporation (NYSE:BSX) Receives Average Rating of "Buy" from Brokerages

Key Points

• Boston Scientific Corporation has received a consensus recommendation of "Buy" from 26 research firms, with an average 1-year price target of $118.04.
• Several analysts, including Robert W. Baird and Barclays, have recently raised their target prices for Boston Scientific, with Barclays setting a new target at $133.00.
• Insider activity shows significant sales, with an executive selling 17,313 shares and a director selling 2,901 shares, indicating a 42.32% and 58.23% decrease in their ownership, respectively.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has received a consensus rating of "Buy" from the twenty-six analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, twenty-two have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $118.1667.

Several analysts have issued reports on the stock. UBS Group upped their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Robert W. Baird raised their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Finally, Barclays lifted their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 over the last quarter. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Caldwell Trust Co purchased a new stake in Boston Scientific during the second quarter valued at about $528,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in Boston Scientific by 72.9% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 145 shares in the last quarter. Valeo Financial Advisors LLC grew its position in Boston Scientific by 4.3% during the second quarter. Valeo Financial Advisors LLC now owns 22,551 shares of the medical equipment provider's stock valued at $2,422,000 after acquiring an additional 930 shares during the last quarter. Osaic Holdings Inc. grew its position in Boston Scientific by 20.0% during the second quarter. Osaic Holdings Inc. now owns 144,745 shares of the medical equipment provider's stock valued at $15,459,000 after acquiring an additional 24,080 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Boston Scientific by 44.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 26,576 shares of the medical equipment provider's stock valued at $2,855,000 after acquiring an additional 8,139 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.3%

NYSE BSX traded down $0.32 during trading on Friday, reaching $96.71. 1,292,899 shares of the stock traded hands, compared to its average volume of 7,684,492. The firm has a market cap of $143.31 billion, a price-to-earnings ratio of 57.57, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. Boston Scientific has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock's 50-day moving average price is $104.25 and its 200 day moving average price is $102.08.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.